Skip to main content

Table 1 Characteristics of completed patients

From: Lung function and radiological findings 1 year after COVID-19: a prospective follow-up

 

Severity group 1

n = 209

Severity group 2

n = 23

Severity group 3

n = 52

Total

n = 284

p-value

Age, years

59.9 (12.5)

61.4 (10.7)

62.7 (9.6)

60.5 (11.9)

0.28

Male sex

105 (50.2%)

14 (60.9%)

38 (73.1%)

157 (55.3%)

0.01

BMI, kg/m2

28.0 (4.8)

27.3 (4.1)

28.0 (4.4)

28.0 (4.7)

0.75

Never-smoker

122 (58.4%)

17 (73.9%)

25 (48.1%)

164 (57.7%)

0.14

Comorbidities

 Pulmonary diseasea

39 (18.7%)

4 (17.4%)

7 (13.5%)

50 (17.6%)

0.69

 Hypertension

82 (39.2%)

5 (21.7%)

25 (48.1%)

112 (39.4%)

0.09

 Diabetes

30 (14.4%)

1 (4.3%)

10 (19.2%)

41 (14.4%)

0.26

 Cardiovascular disease

21 (10.0%)

3 (13%)

4 (7.7%)

28 (9.9%)

0.74

Admission RALE score

3.2 (1.6)

4.1 (1.5)

4.3 (1.7)

3.5 (1.7)

< 0.001

Peak RALE score

3.2 (1.6)

4.2 (1.8)

6.0 (1.6)

6.5 (1.6)

< 0.001

Length of hospital stay, days

9.2 (5.1)

19.9 (6.4)

43.6 (27.5)

16.5 (18.4)

< 0.001

Laboratory findingsb

 Lymphocytes, × 109/L

1.0 (0.5)

0.7 (0.5)

0.5 (0.3)

0.9 (0.5)

< 0.001

 LDH, U/L

514.0 (224.8)

592.5 (221.7)

873.8 (360.1)

590.7 (291.8)

< 0.001

 C-reactive protein, mg/L

81.7 (79.9)

222.3 (120.2)

234.5 (145.4)

121.3 (118.4)

< 0.001

 Ferritin, ng/mL

838.2 (713.6)

1506.1 (1031.9)

2133.3 (1469.0)

1151.3 (1064.2)

< 0.001

 Fibrinogen, g/L

6.4 (1.6)

8.2 (2.2)

21.8 (82.6)

9.5 (36.2)

0.08

 D-dimer, ng/mL

1957.6 (4280.8)

3106.3 (4984.6)

10,994.5 (10,535.6)

3631.2 (6796.3)

< 0.001

  1. Data are n (%) or mean (SD). Severity group 1: mild. Severity group 2: moderate. Severity group 3: severe
  2. BMI body mass index, RALE radiographic assessment of lung edema, LDH lactate dehydrogenase
  3. aPulmonary disease: asthma, obstructive sleep apnea
  4. bAll laboratory findings are peak values except for lymphocytes which is the lowest value